Keystone Symposia Conference | Mobilizing Cellular Immunity for Cancer Therapy

Meeting Program

To view program in "24 hour" time (international) click here.

Sunday, January 11
3:00 - 7:30 PM	Registration	Ballroom Lobby
6:30 - 7:30 PM	Refreshments	Ballroom Lobby
7:30 - 9:30 PM	Keynote Session Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Ballroom 2-3
	Irving L. Weissman, Stanford University, USA Normal and Neoplastic Stem Cell

	Stephen S. Hall, , USA "More Commotion in the Blood:" A Science Writer's View from the Sidelines
Monday, January 12
7:00 - 8:00 AM	Breakfast	Golden Cliff / Eagles
8:00 - 11:00 AM	Tumor Surveillance and Microenvironment Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Ballroom 2-3
	* Robert D. Schreiber, Washington University School of Medicine, USA The Outgrowth of Cancer – A Problem of Disequilibrium
	David H. Raulet, University of California, Berkeley, USA NK Cell Recognition of Ligands on Transformed Cells
	Anna Wasiuk, Dartmouth College, USA Short Talk: Acquired Immune Privilege within the Tumor Microenvironment: Mast Cells Suppress the Development of Protective Anti-Tumor Immunity while Enhancing Tumor-Induced Angiogenesis
	Lisa M. Coussens, University of California, San Francisco, USA Inflammation and Cancer: Insights into Organ-Specific Immune Regulation of Cancer Development
	Jeffrey W. Pollard, Albert Einstein College of Medicine, USA Tumor Educated Macrophages Stimulate Malignant Progression and Enhance Metastasis
9:20 - 9:40 AM	Coffee Break	Ballroom Lobby
11:00 AM-	On Own for Lunch
11:00 AM- 1:00 PM	Poster Setup	Superior / Superior Lobby / Wasatch / Maybird
1:00 - 10:00 PM	Poster Viewing	Superior / Superior Lobby / Wasatch / Maybird
2:30 - 4:30 PM	Workshop 1: Events in the Microenvironment	Ballroom 2
	* Victor H. Engelhard, University of Virginia, USA
	Andrew R. Ferguson, University of Virginia, USA Differential Homing Receptor Expression on T Cells Activated In Distinct Lymphoid Organs Resulting in T Cell Migration to Tumors
	Michelle Li Wen Hong, Biomedical Sciences Institute, Singapore The Role of the Immune System in the Control of Cancer in a Spontaneous Mouse Melanoma Model
	Jennifer Landsberg, Klinik und Poliklinik für Dermatologie und Allergologie, Germany Primary Cutaneous Melanomas in HGFxCdk4R24C Mice Avoid Recognition and Destruction by the Cellular Immune System
	Jacqueline D. Shields, Ecole Polytechnique Federale de Lausanne, Switzerland Lymph Node Mimicry by Tumors Induces Immunological Tolerance in a Complement-Dependent Manner
	Elizabeth D. Thompson, University of Virginia, USA Tumors can Serve as a Primary Site of Naïve T Cell Activation
	Roberta Faccio, Washington University, USA Important Contribution of the Immune System in Regulating the Tumor/Bone Vicious Cycle Independent from Osteoclasts
2:30 - 4:30 PM	Workshop 2: Tolerance and Regulatory Checkpoints	Ballroom 3
	* Dario A.A. Vignali, St. Jude Children's Research Hospital, USA
	Marieke F. Fransen, Leiden University Medical Center, The Netherlands Low Dose Anti-CD40 Activating Therapy in the Tumor-Draining Area is as Effective in Generating an Anti-Tumor CTL Response as a High Dose Systemic Therapy, with Decreased Toxicity
	Lukas Kremmler, Netherlands Cancer Institute, Netherlands The Role of PD-1 on MTOC Localization during the “Kiss of Death”
	Amanda L. Sherwood, University of Western Australia, Australia Dual Control of Anti-Tumor CD8 and Tumor-Promoting CD4 T Cells through the PD-1/PD-L1 Pathway

	Jaikumar Duraiswamy, Emory University School of Medicine, USA Programmed Death-1 Localization at the Immune Synapse is Different in Exhausted Versus Effector LCMV Specific T Cells
	Andreas Bonertz, German Cancer Research Center, Germany Regulatory T Cells Exhibit Highly Diverse Recognition Patterns of Tumor Antigens and Their Depletion Boosts the Reactivity of Tumor-Specific T Cells in Colorectal Carcinoma Patients
	Joseph F. Grosso, Johns Hopkins School of Medicine, USA Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Tolerized CD8 T Cells
2:30 - 4:30 PM	Workshop 3: gammadelta and NK Cells	Ballroom 1
	* Jean-Jacques Fournié, INSERM U563, France Catch, Kiss and Kill: Gamma Delta T Cell-Based Cancer Immunotherapies
	Massimo Massaia, Universita' degli Studi di Torino, Italy Accumulation of Terminally Differentiated Effector Vgamma9/Vdelta2 T Cells in Patients with Chronic Lymphocytic Leukemia: a Novel Mechanism of Immunoediting Driven by the Mevalonate Pathway of Tumor Cells
	Volker Kunzmann, Medizinische Klinik und Poliklinik II, Germany gamma delta T Cell-Mediated Immunotherapy for Cancer: Current Reality and Future Options
	Julie Dechanet-Merville, Université Bordeaux 2, France Protection from Cancer After Kidney Transplantation is Correlated with Cytomegalovirus-Induced gamma delta T Cells
	Hollie J. Pegram, Peter MacCallum Cancer Centre, Australia Gene Modified Natural Killer Cells for Cancer Immunotherapy
	Nourredine Himoudi, Institute of Child Health and Great Ormond Street Hospital, UK The Bone Marrow Derived Interferon Producing Killer Dendritic Cells (IKDC) Subset of Cells Account for the Tumoricidal Activity of Unpulsed Dendritic Cells by Migrating into Tumors and Cross Presenting Antigens in vitro and in vivo
4:30 - 5:00 PM	Coffee Available	Ballroom Lobby
5:00 - 7:00 PM	Homing to Tumor Sites - You Can't Always Get Where You Want Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Ballroom 2-3
	Owen N. Witte, University of California, Los Angeles, USA Tracking Responses – It’s Nice Having a PET (Scanner)

	Rachael A. Clark, Brigham and Women's Hospital, USA Short Talk: Imiquimod Enhances IFNgamma Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin
	* Thomas F. Gajewski, University of Chicago, USA T Cells and Tumors — An Avoidable Attraction

	George Coukos, University of Pennsylvania, USA “Seek (in the Soil) and You Shall Find”: Interrogation of the Tumor Microenvironment Reveals Critical Mechanisms Modulating Homing of T cells to Tumors
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Superior / Superior Lobby / Wasatch / Maybird
7:30 - 10:00 PM	Poster Session 1 Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Superior / Superior Lobby / Wasatch / Maybird
Tuesday, January 13
7:00 - 8:00 AM	Breakfast	Golden Cliff / Eagles
8:00 - 11:00 AM	Immunologic Restraint Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Ballroom 2-3
	* James P. Allison, Memorial Sloan-Kettering Cancer Center, USA Checkpoint Blockade in Tumor Immunotherapy: New Insights and Opportunities
	Alexander Y. Rudensky, University of Washington, USA Cell-Mediated Control of Immune Mediated Inflammation
	Sergio A. Quezada, Memorial Sloan-Kettering Cancer Center, USA Short Talk: CTLA-4 Blockade Prevents de Novo in vivo Generation of Foxp3+ and IL10+ Regulatory T Cells and Promotes Potent Tumor Rejection Upon Transfer of Tumor-Reactive CD4+ T Cells
	Benoît J. Van den Eynde, University of Louvain, Belgium Fighting Tumoral Immune Resistance
	Richard A. Flavell, Yale University School of Medicine, USA Why TGF-beta May Not Be Good For You
9:20 - 9:40 AM	Coffee Break	Ballroom Lobby
11:00 AM-	On Own for Lunch
11:00 AM- 1:00 PM	Poster Setup	Superior / Superior Lobby / Wasatch / Maybird
1:00 - 10:00 PM	Poster Viewing	Superior / Superior Lobby / Wasatch / Maybird
2:30 - 4:30 PM	Workshop 4: Tumor Antigens	Ballroom 2
	* Cornelis J. Melief, Leiden University Medical Center, The Netherlands
	Mirjam H.M. Heemskerk, Leiden University Medical Center, Netherlands SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens
	John J. Miles, Queensland Institute of Medical Research, Australia The T Cell Receptor Repertoire to Epstein-Barr Virus
	Inge Jedema, Leiden University Medical Center, Netherlands High Avidity HLA-A2-Restricted CD8+ T Cells Against the Wilms Tumor Protein (WT1) Can Only be Isolated from HLA-A2 Negative Donors not Subjected to HLA-A2-Mediated Thymic Deletion
	Karen Hastings, University of Arizona College of Medicine, Phoenix, USA Lysosomal Thiol Reductase GILT is Important in Immune Recognition of Melanoma Antigen TRP1
	Michel Kester, Leiden University Medical Center, The Netherlands A Proteomics Approach to Identification of Antigens for T Cell Mediated Immunotherapy
	Peter A. Savage, Memorial Sloan-Kettering Cancer Center, USA Repertoire Selection of Tumor-Infiltrating T Cell Populations in a Mouse Model of Spontaneous Prostate Cancer
2:30 - 4:30 PM	Workshop 5: Vaccines	Ballroom 3
	* Jeffrey J. Molldrem, University of Texas MD Anderson Cancer Center, USA
	Alice Yewdall, New York University, USA Peptide-Loaded Dendritic Cell Vaccines Require Endogenous Antigen Presenting Cells for Maximal Naïve CD8+ T Cell Activation
	Kimberly R. Jordan, University of Colorado Health Sciences Center, USA Protective Mimotope Vaccines Elicit a Less Diverse Repertoire of T Cells that Produces IFN-gamma and have Higher Affinity for TAA

	Lisa M. McEwen, University of Pittsburgh, USA Mechanistic Study of the DOTAP/E7 Therapeutic Vaccine
	Hideho Okada, University of Pittsburgh, USA Induction of Type-1 CTL Responses Against Novel Glioma-Associated Antigen -Derived Epitopes Epha2 (883-891) and IL-13Ralpha2 (345-353)
	Lionel J. Apetoh, Brigham and Women's Hospital, Harvard Medical School, USA Endogenous Danger Signals Ferried by Dying Tumor Cells to Dendritic Cells Dictate the Efficacy of Anticancer Chemotherapy and Radiotherapy
2:30 - 4:30 PM	Workshop 6: Macrophages/Inflammation/Tumor Promotion	Ballroom 1
	* Suzanne Ostrand-Rosenberg, University of Maryland, USA Myeloid -Derived Suppressor Cells Inhibit T Cell Activation and Anti-Tumor Immunity by Sequestering Cystine and Cysteine
	Marta Coscia, Università di Torino, Italy Clinically Relevant Doses of Zoledronic Acid Efficiently Target Tumor Associated Macrophages and Cancer Microenvironment Prolonging Disease-Free and Overall Survival in a Transgenic Model of Human Breast Cancer
	Matthew R. Porembka, Washington University in St. Louis, USA Zoledronate Impairs Intratumoral Accumulation of Myeloid Derived Suppressor Cells Resulting in Smaller Tumors and Prolonged Survival
	Brent H. Koehn, La Jolla Institute for Allergy & Immunology, USA Tolerogenic Programming of CD8 T Cells by B Cell APC
	George C. Prendergast, Lankenau Institute for Medical Research, USA IDO Pathway in Cancer and Immune Escape
	Ainhoa Perez-Diez, NIAID, National Institutes of Health, USA Tumor Specific CD4 Cells, but not CD8 Cells, Induce Phenotypic and Functional Changes on Tumor Associated Macrophages
4:30 - 5:00 PM	Coffee Available	Ballroom Lobby
5:00 - 7:00 PM	Innate Conditioning: 'Finis Origine Pendet' Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Ballroom 2-3

	Giorgio Trinchieri, National Cancer Institute at Frederick, USA Innate Resistance, Inflammation, and Cancer
	* Kenneth M. Murphy, Washington University School of Medicine, USA Transcriptional Regulation of Dendritic Cell Subsets for Cross-Presentation and Tumor Rejection
	Federica Sallusto, Institute for Research in Biomedicine, Switzerland Chemokine Receptors - Getting You Where You Need to Go
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Superior / Superior Lobby / Wasatch / Maybird
7:30 - 10:00 PM	Poster Session 2 Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Superior / Superior Lobby / Wasatch / Maybird
Wednesday, January 14
7:00 - 8:00 AM	Breakfast	Golden Cliff / Eagles
8:00 - 11:00 AM	Tumor Antigens: A Turn-On or a Turn-Off? Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Ballroom 2-3
	Bruce W. Robinson, University of Western Australia, Australia Chemotherapy as a Strategy to Induce Antigen Presentation
	Mark J. Smyth, Peter MacCallum Cancer Centre, Australia Combination Chemo-Immunotherapies: Looking for Synergy
	Mark P. Chao, Stanford University, USA Short Talk: CD47 Regulates a Mechanism of Immune Evasion in Acute Myeloid Leukemia Stem Cells
	* Laurence Zitvogel, Institut Gustave Roussy, France Novel Subsets of NK Cells and Regulation during Cancer Progression: Regulatory NK Cells and DC-like NK Cells
	Jay A. Berzofsky, National Cancer Institute, National Institutes of Health, USA Role of NKT Cell Subsets in the Regulation of Anti-Tumor Immunity
9:20 - 9:40 AM	Coffee Break	Ballroom Lobby
11:00 AM-	On Own for Lunch
11:00 AM- 1:00 PM	Poster Setup	Superior / Superior Lobby / Wasatch / Maybird
1:00 - 10:00 PM	Poster Viewing	Superior / Superior Lobby / Wasatch / Maybird
4:30 - 5:00 PM	Coffee Available	Ballroom Lobby
5:00 - 7:00 PM	Adoptive T Cell Therapy Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Ballroom 2-3
	* Philip D. Greenberg, University of Washington, USA Building a T Cell Response Effective for Eradicating Tumors

	Mark E. Dudley, National Cancer Institute, National Institutes of Health, USA Clinical Trials with Cell and Gene Therapy for Patients with Melanoma
	Gert Riethmüller, University of Munich, Germany Late Breaking Short Talk: The Promise of T Cell-Engaging BiTE Antibodies for Cancer Therapy
	Nicholas P. Restifo, National Cancer Institute, National Institutes of Health, USA Enhancing the Power of Tumor-Specific T Cells
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Superior / Superior Lobby / Wasatch / Maybird
7:30 - 10:00 PM	Poster Session 3 Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Superior / Superior Lobby / Wasatch / Maybird
Thursday, January 15
7:00 - 8:00 AM	Breakfast	Golden Cliff / Eagles
8:00 - 11:00 AM	Vaccines to Treat Cancer Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Ballroom 2-3
	* Ralph M. Steinman, Rockefeller University, USA Vaccination with Cancer Antigens Selectively Targeted to Dendritic Cells in situ
	Drew M. Pardoll, Johns Hopkins School of Medicine, USA Dissecting and Manipulating the Balance between Procarcinogenic and Anti-Carcinogenic Immunity
	Nina Bhardwaj, New York University School of Medicine, USA Targeting Dendritic Cells to Enhance Anti-Cancer Immunity

	Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA Immune Responses Mediated By CTLA-4 Blockade
9:20 - 9:40 AM	Coffee Break	Ballroom Lobby
11:00 AM-	On Own for Lunch
2:30 - 4:30 PM	Workshop 7: Adoptive Therapy	Ballroom 2
	* Stanley R. Riddell, Fred Hutchinson Cancer Research Center, USA
	Salvatore Fiorenza, Diamantina Institute for Cancer, Immunology and Metabolic Medicine, Australia Central Memory CD8 T Cells are More Potent than Effector Memory T Cells and Show Heightened Responses to a Local Inflammatory Stimulus
	Michele L. Martin, University of Victoria, Canada Identifying Tumor-Specific Determinants of T Cell Infiltration After Adoptive Immunotherapy
	Tobias Seibel, German Cancer Research Center, Germany Local Low Dose Irradiation Triggers Tumor Infiltration by Adoptively Transferred and Host T Lymphocytes and Enhances Immunotherapy in Mice
	Ingunn M. Stromnes, University of Washington Health Sciences, USA Targeting Cbl-b in Antigen-Specific CD8+ T Cells for Adoptive Immunotherapy of Progressive Leukemia in a Murine Model
	Robbert Spaapen, Universitair Medisch Centrum Utrecht, The Netherlands Minor Histocompatibility Antigen Specific CD4+ T Cells for Adoptive Immunotherapy of Multiple Myeloma in Xenografted rag2-/-ãc-/- Mice
	Eduardo Davila, Louisiana State University, USA Overexpressing TLR2-MyD88 in Tumor-specific CD8 T cells Enhances Antitumor Activity
2:30 - 4:30 PM	Workshop 8: Engineering Tumor Reactivity with TCRs/CARs	Ballroom 3
	* Michael Jensen†, City of Hope, USA
	Zelig Eshhar, Weizmann Institute of Science, Israel Redirected, Genetically Engineered T Cells for Adoptive Immunotherapy of Cancer
	Gavin M. Bendle, Netherlands Cancer Institute, The Netherlands TCR Gene Transfer-Induced GvHD Results in Lethal Pathology in Mice
	Andy K. Sewell, University of Cardiff, UK Enhanced TCRs for Mobilizing Cellular Immunity for Cancer Therapy
	Cor H. J. Lamers, Erasmus MC, Daniel den Hoed Cancer Center, Netherlands Humoral and Cellular Immune Responses Towards the scFvG250 Transgene in the Rotterdam Retargeted T Cell Therapy Trial
	Laura A. Johnson, National Cancer Institute, National Institutes of Health, USA High Affinity T Cell Receptor Gene Therapy Breaks Tolerance and Elicits Autoimmunity and Cancer Regression
	Reno Debets, Erasmus MC-Daniel, Netherlands TCR Gene Transfer: MHC Class I and II-Restricted MAGE Epitopes as Melanoma-Specific Immune Targets
4:30 - 5:00 PM	Coffee Available	Ballroom Lobby
5:00 - 6:40 PM	HPV: Almost a Success Story, Lessons to be Learned Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Ballroom 2-3
	Ian H. Frazer, University of Queensland, Australia Preventing Cervical Cancer through Immunisation
	* Cornelia L. Trimble, Johns Hopkins University School of Medicine, USA At Your Cervix: Immune Therapies for HPV Disease
	Cornelis J. Melief, Leiden University Medical Center, The Netherlands Induction of Objective Clinical Responses by Therapeutic Vaccination with Synthetic Long Peptides in Patients with High Grade HPV16-induced Premalignant Vulva Lesions

6:40 - 7:00 PM	Concluding Remarks Registered attendees for this meeting can view Abstracts for this session starting on 12/11/2008	Ballroom 2-3
	Ralph M. Steinman, Rockefeller University, USA Gaining Traction on Translation
8:00 - 9:00 PM	Social Hour w/ Lite Bites	Ballroom 1-2
8:00 - 11:00 PM	Entertainment	Ballroom 1-2
Friday, January 16
	Departure
*=Session Chair †=Speaker invited, not yet responded.

Keystone Symposia would like to thank the sponsor of this meeting for their generous support:

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

We gratefully acknowledge the organizations that provide Keystone Symposia with additional support, such as marketing and advertising...

Click here to view these companies

Studies demonstrating the role of the immune system in the development and/or prevention of cancer, and elucidating the obstacles limiting an effective immune response to progressing tumors, have suggested strategies for manipulating the immune system to promote eradication of established tumors. This meeting will bring together investigators probing innate and adaptive immune systems, as well as regulatory pathways, to provide a context for developing effective tumor immunotherapies. The major objectives will be as follows: (1) explore the dual roles that components of the immune system can play early in developing malignancies, leading to protection or tumor promotion; (2) examine the mechanisms by which immune responses can be subverted by the malignant process; (3) describe the rationale for and potential benefit of immunotherapeutic strategies currently being explored for modulating adaptive immunity to achieve therapeutic anti-tumor responses; and (4) discuss the rationale for concurrently employing multiple immunosupportive modalities to enhance immunotherapeutic strategies.

Mobilizing Cellular Immunity for Cancer Therapy (A3)